Comparative Pharmacology
Head-to-head clinical analysis: DIUPRES 500 versus HY PAM 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIUPRES 500 versus HY PAM 25.
DIUPRES-500 vs HY-PAM "25"
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diupres-500 is a combination of chlorothiazide, a thiazide diuretic, and reserpine, a Rauwolfia alkaloid. Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing water excretion. Reserpine depletes catecholamines from central and peripheral nerve terminals by blocking vesicular monoamine transporter 2 (VMAT2), leading to decreased sympathetic outflow and vasodilation.
Hydroxyzine pamoate is a piperazine antihistamine that acts as a histamine H1-receptor antagonist, thereby suppressing histamine-mediated responses in the skin and mucous membranes. Additionally, it exhibits anxiolytic and sedative properties through central nervous system depression via inhibition of subcortical regions.
Oral, 1 tablet (hydrochlorothiazide 50 mg + reserpine 0.125 mg) once daily, increased up to 2 tablets per day if needed.
25 mg orally once daily, preferably at bedtime, for short-term treatment of insomnia.
None Documented
None Documented
Reserpine: 50-100 hours (prolonged; clinical effect persists for days due to irreversible MAO depletion). Hydrochlorothiazide: 6-15 hours (biphasic; terminal phase reflects renal elimination).
Terminal elimination half-life 6-8 hours in healthy adults; prolonged to 12-18 hours in renal impairment (CrCl <30 mL/min) and in elderly patients.
Renal: ~50% (primarily hydrochlorothiazide), Fecal: ~50% (primarily reserpine).
Primarily renal (60-70% unchanged drug), with 30-40% biliary/fecal elimination as metabolites.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination